Inclusion of rifapentine in the Global Drug Facility catalogue

The Community Research Advisors Group urges Sanofi to submit a bid for rifapentine to be included in the Stop TB Partnership's Global Drug Facility catalogue.

On February 1, 2016 the Stop TB Partnership's Global Drug Facility and its procurement agent, IDA Foundation, released an Invitation to Bid for eligible suppliers to include tuberculosis medications in the Global Drug Facility (GDF) catalogue. For the first time, the Invitation to Bid includes rifapentine (150mg film coated tablets) among the eligible antituberculosis medications. Rifapentine is approved by the US Food and Drug Adminsitration to treat active TB disease, and to shorten treatment of TB infection.

Therefore, on February 17, 2016 the Community Research Advisors Group (CRAG) sent an open letter to Sanofi strongly encouraging the company to submit a bid for rifapentine to be included in the GDF catalogue by the February 29th deadline. CRAG is the community advisory body to the U.S. Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium (TBTC).

“Adding rifapentine to the catalogue now would raise awareness of this new product and enable the GDF to proactively work with interested National TB Programs to access the drug…”

In addition to hearing about Sanofi’s plans regarding the GDF Invitation to Bid, in the letter CRAG requests to receive an updated list of the countries in which Sanofi is taking steps to register rifapentine under an indication to treat TB infection.

To read the open letter, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Community Research Advisors Group (CRAG)

Published: Feb. 21, 2016, 7:33 p.m.

Last updated: March 2, 2016, 6:29 p.m.

Tags: Access, Advocacy, CRAG

Print Share